Dengvaxia for Dengue Fever
Dengvaxia, approved by the FDA, is for individuals 9-16 in dengue-endemic areas. Controversy arose due to differing vaccine performance in those with and without previous dengue infection. The vaccine can lead to severe dengue in seronegative individuals and was misused in the Philippines, causing a vaccine hesitancy crisis. It’s only necessary if living in endemic areas.
Dengvaxia for Dengue Fever Read More »
You must be logged in to post a comment.